^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JD001

    i
    Other names: JD001, allogenic CD19-CAR-NK cells
    Associations

    News

    Trials
    Company:
    Beijing JD Biotech, Xuzhou Medical University
    Drug class:
    CD19 inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=12, Recruiting, Xuzhou Medical University
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    JD001